Outpatient Facility Coding Alert - 2003 Issue 32
FEDS SEEK INFO ON BRISTOL-MYERS COMPLIANCE REVIEW
Subscribe or sign in to view the full article.
Article Overview
This article covers a pharma compliance and enforcement update involving government interest in a drugmaker’s internal review of sales, marketing, and pricing practices. It is relevant to readers tracking healthcare fraud enforcement, pharmaceutical compliance, Medicaid-related pricing issues, and related federal oversight activity. The piece also notes the broader compliance topics being examined and the agencies involved.
Why This Topic Matters
It helps compliance, legal, and healthcare industry readers understand the types of government scrutiny affecting pharmaceutical manufacturers and the broad categories of pricing and marketing practices under review.
What You Will Learn
- What areas of pharmaceutical compliance and pricing are under government scrutiny
- Which federal and state entities are involved in health care fraud enforcement
- Why internal compliance reviews can attract regulatory attention
- How Medicaid-related pricing and rebate issues are framed in enforcement discussions
Who Should Read This
- Healthcare compliance professionals
- Pharmaceutical legal and regulatory teams
- Health law attorneys
- Revenue integrity and audit professionals
- Policy and enforcement analysts
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com